Decibel Therapeutics logo
Decibel Therapeutics DBTX

Quarterly report 2023-Q2
added 08-11-2023

report update icon

Decibel Therapeutics Market Cap 2011-2026 | DBTX

As of May 01, 2026 Decibel Therapeutics has a market cap of $ 123 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Decibel Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
102 M 93.5 M - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
102 M 93.5 M 97.8 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
6.69 M $ 0.88 - $ 6.47 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
467 M $ 4.12 0.37 % $ 441 M usaUSA
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
AlloVir AlloVir
ALVR
13.1 M - 4.14 % $ 49.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
8.59 B $ 9.7 1.09 % $ 627 M usaUSA
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
168 B - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
3.19 B $ 21.83 -2.76 % $ 3.62 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
1.62 M - - $ 269 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
22.1 M - - $ 10.1 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
81.2 B - - $ 96.9 B britainBritain
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 5.0 1.42 % $ 801 M britainBritain
Atreca Atreca
BCEL
49 M - -11.76 % $ 5.79 M usaUSA
Berkeley Lights Berkeley Lights
BLI
117 M - -7.31 % $ 87 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
960 M - -10.95 % $ 876 K usaUSA
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.43 B - - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
1.82 M - - $ 3.74 B usaUSA
Cerus Corporation Cerus Corporation
CERS
496 M $ 2.91 43.35 % $ 555 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Caladrius Biosciences Caladrius Biosciences
CLBS
3.58 M - -16.75 % $ 25.8 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
52.7 M - - $ 231 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
BioNTech SE BioNTech SE
BNTX
62.9 B $ 96.45 -6.77 % $ 27.2 B germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
6.33 M - -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
1.2 B - - $ 2.18 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
363 M $ 1.44 - $ 235 M franceFrance
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
1.73 B - - $ 2.02 B usaUSA
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
114 M - - $ 28.6 M usaUSA
Editas Medicine Editas Medicine
EDIT
206 M $ 2.9 -3.33 % $ 257 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
4.81 M $ 3.04 -4.7 % $ 5 M israelIsrael
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
3.11 M - -9.21 % $ 2.55 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
6.08 M $ 18.7 2.33 % $ 59.8 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
6.15 M - -5.68 % $ 8.28 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
66.3 M $ 0.78 -0.37 % $ 27.9 M israelIsrael
Applied Therapeutics Applied Therapeutics
APLT
541 M - - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada